Chimeric antigen receptor T (CAR-T) cell therapy has transformed the field of immunology with outstanding success in treating hematological cancers. CARs are cell-surface receptors designed to navigate T cells toward a specific antigen. The extracellular domain of the CAR originates from an antibody fragment, allowing the cell to recognize tumor-associated antigens (TAAs). Tumors with low or no major histocompatibility complex (MHC) expression can be challenging for T cells to attack. However, CAR-T cells target cancer cells independently of MHC presentation and bind directly to TAAs. Once T cells are harvested from the donor's blood, the CAR construct is introduced into T cells through viral vector transduction. The engineered CAR-T cells are then cultured and expanded ex vivo with supplementation of cytokines before being injected into the patient. Since the first FDA-approved CAR therapy, Kymriah was approved in 2017, many similar therapeutics, such as Yescarta, Tecartus, and Breyanzi, have been introduced. These treatments have had remarkable success, with patients achieving complete remission (CR) 30-70% of the time and, in some trials, over 90% . However, many studies still depict CARs as ineffective because of a lack of persistence.